A PHASE 1/2 DOSE ESCALATION STUDY OF THE BCL-2 INHIBITOR ZN-d5 AND THE WEE1 INHIBITOR ZN-c3 IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA ZN-d5-004C
Brief description of study
This study is designed for patients with acute myeloid leukemia.
The study is a phase 1/2 dose escalation study of the BCL-2 Inhibitor ZN-d5 and the WEE1 inhibitor ZN-c3 in subjects with acute myeloid leukemia (ZN-d50004C).
Clinical Study Identifier: s22-01161
Principal Investigator:
Mohammad Maher Abdul Hay.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.